The use of raloxifene in osteoporosis treatment.

Détails

ID Serval
serval:BIB_14F0716E165C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
The use of raloxifene in osteoporosis treatment.
Périodique
Expert opinion on pharmacotherapy
Auteur⸱e⸱s
D'Amelio P., Isaia G.C.
ISSN
1744-7666 (Electronic)
ISSN-L
1465-6566
Statut éditorial
Publié
Date de publication
05/2013
Peer-reviewed
Oui
Volume
14
Numéro
7
Pages
949-956
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Osteoporosis is a common disease characterized by the occurrence of fragility fractures. Major osteoporotic fractures are associated with decreased quality of life and high costs.
This review summarizes clinical data on raloxifene (RLX), a second generation selective estrogen-receptor modulator (SERM), currently approved for the treatment of postmenopausal osteoporosis. RLX has estrogen effects on bone and lipid profile, whereas it has anti-estrogen effects on uterus and breast cells. Its main side effects are hot flushes and venous thromboembolism. Literature searches were conducted to retrieve articles reporting RLX clinical trial data. For comparison of safety and efficacy, post-marketing studies on RLX were included.
RLX is effective in reducing vertebral fracture risk in osteoporotic women, it is safe and its ability to prevent breast cancer has to be considered in the analyses of cost/effect and of the ideal candidate to this treatment. RLX has to be avoided in patients with previous history of venous thromboembolism.
Mots-clé
Bone Density Conservation Agents/adverse effects, Bone Density Conservation Agents/pharmacology, Bone Density Conservation Agents/therapeutic use, Breast Neoplasms/prevention & control, Clinical Trials as Topic, Cost-Benefit Analysis, Female, Humans, Osteoporosis, Postmenopausal/drug therapy, Osteoporotic Fractures/prevention & control, Raloxifene Hydrochloride/adverse effects, Raloxifene Hydrochloride/pharmacology, Raloxifene Hydrochloride/therapeutic use, Selective Estrogen Receptor Modulators, Spinal Fractures/prevention & control
Pubmed
Web of science
Création de la notice
14/01/2020 8:00
Dernière modification de la notice
15/01/2020 6:26
Données d'usage